


BIBLIOGRAPHY

Clinical Research



The Thrombosis Research Institute (TRI) has published over 75 papers from several key studies...



TRI has been at the centre of the global understanding of thrombosis for several decades, producing the highest calibre research into the condition.

After decades of conducting important trials we expanded our research to include Real World outcomes studies, strengthening the chain of evidence beyond clinical trials and generating new data to improve healthcare delivery and patient outcomes.

The recent published outputs of our clinical research studies are summarised in this document.

Updated 05.2023

1. Mantovani LG, Cozzolino P, Ferrara P, Virdone S, Camm AJ, Verheugt FWA, Bassand JP, Turpie AGG, Hacke W, Kayani G, Goldhaber SZ, Goto S, Pieper K, Gersh BJ, Fox KAA, Haas S, van Eickels M, Kakkar A, for the GARFIELD-AF investigators. **Healthcare resource utilization in patients with newly diagnosed atrial fibrillation: A global analysis from the GARFIELD-AF registry.** Healthcare (2023) doi: 10.3390/healthcare11050638.
2. Haas, S, Camm, JA, Harald, D, et al. **GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide.** Clin Res Cardiol (2022). <https://doi.org/10.1007/s00392-022-02079-y>.
3. Camm CF, Virdone S, Goto S, Bassand JP, van Eickels M, Haas S, Gersh BJ, Pieper K, Fox KAA, Misselwitz F, Turpie AGG, Goldhaber SZ, Verheugt F, Camm AJ, Kayani G, Panchenko E, Oh S, Luciardi HL, Sawhney JPS, Connolly SJ, Angchaisuksiri P, Cate H, Eikelboom JW, Kakkar AK, for the GARFIELD investigators. **Association of body mass index with outcomes in patients with newly diagnosed atrial fibrillation: GARFIELD-AF.** doi: <http://dx.doi.org/10.1136/openhrt-2022-002038>.
4. Johnson, D, Pieper, K, Yang, S. **Treatment-specific marginal structural Cox model for the effect of treatment discontinuation.** Pharmaceutical Statistics. 2022; 1- 17. doi:10.1002/pst.2211.
5. van Husen G, Virdone S, Pieper K, Kayani G, Fox KAA. **Universal Clinician Device for improving risk prediction and management of patients with atrial fibrillation: an assumed benefit analysis.** European Heart Journal - Digital Health, ztac011, DOI: <https://doi.org/10.1093/ehjdh/ztac011>.
6. Johnson, D, Pieper, K, Yang, S. **Treatment-specific marginal structural Cox model for the effect of treatment discontinuation.** Pharmaceutical Statistics. 2022; 1- 17. doi:10.1002/pst.2211.
7. Fox KAA, Virdone S, Bassand JP, Camm AJ, Goto S, Goldhaber SZ, Haas S, Kayani G, Koretsune Y, Misselwitz F, Oh S, Piccini JP, Parkhomenko A, Sawhney JPS, Stepinska J, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF investigators. **Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry.** BMJ Open. 2022 Jan 7;12(1):e049933. doi: 10.1136/bmjopen-2021-049933. PMID: 34996784; PMCID: PMC8744109.
8. Farjat AE, Virdone S, Thomas LE, Kakkar AK, Pieper KS, Piccini JP. **The importance of the design of observational studies in comparative effectiveness research: Lessons from the GARFIELD-AF and ORBIT-AF registries.** Am Heart J. 2022 Jan;243:110-121. doi: 10.1016/j.ahj.2021.09.003. Epub 2021 Sep 13. PMID: 34529945.
9. Pope MK, Hall TS, Schirripa V, Radic P, Virdone S, Pieper KS, Le Heuzey JY, Jansky P, Fitzmaurice DA, Cappato R, Atar D, Camm AJ, Kakkar AK; GARFIELD-AF investigators. **Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data.** BMJ. 2021 Oct 27;375:e066450. doi: 10.1136/bmj-2021-066450. PMID: 34706884; PMCID: PMC8548918.
10. Cools F, Johnson D, Camm AJ, Bassand J-P, Verheugt FWA, Yang S, Tsiatis A, Fitzmaurice DA, Goldhaber SZ, Kayani G, Goto S, Haas S, Misselwitz F, Turpie AGG, Fox KAA, Pieper KS, Kakkar AK for the GARFIELD-AF Investigators. **Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF Registry.** J Thromb Haemost. 2021 Jun 1. doi: 10.1111/jth.15415.

11. Sayin BY, Mahameed WAL, Ragy HI, Elabhary A, Virdone S, Kakkar AJ, Ersanli M, Oto A. **Middle East Treatment Strategies and Clinical Outcomes in Patients with Atrial Fibrillation: One-Year Follow-up Data from Garfield-AF Study.** *Advances in Therapy* volume 38, pages2391–2405 (2021). doi: 10.1007/s12325-021-01670-5.
12. Fox KAA, Virdone S, Pieper KS, Bassand J-P, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Kayani G, Oto A, Misselwitz F, Piccini JP, Dalgaard F, Turpie AGG, Verheugt FWA and Kakkar AK, for the GARFIELD-AF Investigators. **GARFIELD-AF risk score for mortality, stroke and bleeding within 2 years in patients with atrial fibrillation.** *Eur Heart J Qual Care Clin Outcomes.* 2021 Apr 21:qcab028. doi: 10.1093/ehjqcco/qcab028.
13. Pope MK, Atar D, Svilaas A, Hole T, Nielsen JD, Hintze U, Crisby M, Raatikainen P, Airaksinen KEJ, Virdone S, Pieper K, Kayani G, Le Heuzey J-Y, Steffel J, Stepinska J, Bassand J-P, Camm AJ, for the GARFIELD-AF Investigators. **Risk profile, Antithrombotic Treatment and Clinical Outcomes of patients in Nordic Countries with Atrial Fibrillation-Results from the GARFIELD-AF Registry.** *Annals of Medicine* 53:1, 485-494, DOI:10.1080/07853890.2021.1893897.
14. Gibbs H, Freedman B, Rosenqvist M, Virdone S, Al Mahmeed W, Ambrosio G, Camm AJ, Connolly SJ, Jacobson B, Jerjes-Sanchez C, Kayani G, Oto A, Panchenko E, Ragy H, Kakkar AJ, for the GARFIELD-AF Investigators. **Clinical outcomes in asymptomatic and symptomatic patients with newly diagnosed atrial fibrillation in GARFIELD-AF: Implications for screening for atrial fibrillation.** *American Journal of Medicine*, Vol 000, No 000, 2021. [https://www.amjmed.com/article/S0002-9343\(21\)00096-6/pdf](https://www.amjmed.com/article/S0002-9343(21)00096-6/pdf).
15. Ambrosio G, Camm AJ, Bassand JP, Corbalan R, Kayani G, Carluccio E, Mantovani LG, Virdone S, Kakkar AK; GARFIELD-AF Investigators. **Characteristics, treatment, and outcomes of newly diagnosed atrial fibrillation patients with heart failure: GARFIELD-AF.** *ESC Heart Fail.* 2021 Jan 12. doi: 10.1002/ehf2.13156. Epub ahead of print. PMID: 33434417. <https://pubmed.ncbi.nlm.nih.gov/33434417/>.
16. Bassand J-P, Virdone S, Badoz M, Verheugt FWA, Camm AJ, Cools F, Fox KAA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Misselwitz F, Pieper KS, Turpie AGG, van Eickels M, Kakkar AJ, for the GARFIELD-AF Investigators. **Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry.** *Bloodadvances.* 2021;5(4): 1081-1091. <https://www.sciencedirect.com/science/article/pii/S2473952921001300>.
17. Camm AJ, Fox KAA, Virdone S, Bassand J-P, Fitzmaurice DA, Berchuck SI, Gersh BJ, Goldhaber SZ, Goto S, Haas S, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Cappato R, Kakkar AJ, for the GARFIELD-AF investigators. **Comparative effectiveness of oral anticoagulants in everyday practice.** *Camm AJ, et al. Heart* 2021; 0:1–9. doi:10.1136/heartjnl-2020-318420. <https://heart.bmj.com/content/early/2021/02/15/heartjnl-2020-318420>.
18. Jaap S, Hemels MEW, Xhaet O, Bongaerts MCM, de Wolf A, Groenemeijer BE, Heyse A, Hoogslag P, Voet J, Herrman J-P R, Vervoort G, Hermans W, Wollaert B, Boersma LVA, Hermans K, Lucassen A, Verstraete S, Adriaansen HJ, Mairesse GH, Terpstra WF, Faes D, Pieterse M, Virdone S, Verheugt FWA, Cools F, Ten Cate H, for the GARFIELD-AF investigators. **Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD-AF registry.** *J Thromb Haemost.* 2020 Sep 4. doi: 10.1111/jth.15081.
19. Camm AJ, Cools F, Virdone S, Bassand J-P, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S, Haas S, Mantovani LG, Kayani G, Turpie AGG, Verheugt FWA, Kakkar AJ, for the GARFIELD-AF Investigators. **Mortality in Patients with Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants.** *J Am Coll Cardiol.* 2020; 76(12):1425–36. <https://www.sciencedirect.com/science/article/pii/S0735109720361052?via%3Dihub>.
20. Loring Z, Mehrotra S, Piccini JP, Camm AJ, Carlson D, Fonarow GC, Fox KAA, Peterson ED, Pieper K, Kakkar AK, **Machine Learning Does Not Improve Upon Traditional Regression in Predicting Outcomes in Atrial Fibrillation: An Analysis of the ORBIT-AF and GARFIELD-AF Registries.** *EP Europace*, euaa172. <https://doi.org/10.1093/europace/euaa172>.

21. Bassand J-P, Aparenteng PN, Atar D, Camm AJ, Cools F, Corbalan R, Fitzmaurice DA, Fox KAA, Goto S, Haas S, Hacke W, Jerjes-Sanchez C, Koretsune Y, Le Heuzey J-Y, Sawhney JPS, Oh S, Stepińska J, ten Cate V, Verheugt FWA, Kayani G, Pieper KS, Kakkar AK, for the GARFIELD-AF Investigators. **GARFIELD-AF (Global Anticoagulant Registry in the FIELD – Atrial Fibrillation), a worldwide prospective registry of patients with atrial fibrillation at risk of stroke.** *Future Cardiology* 2020 Jul 22. doi: 10.2217/fca-2020-0014.
22. Seelig J, Verheugt FWA, M. E. W. Hemels MEW, Illingworth L, Lucassen A, Adriaansen H, Bongaerts MCM, Pieterse M, Herrman JPR, Hoogslag P, Hermans W, Groenemeijer BE, Boersma LVA, Pieper K, ten Cate H, and on behalf of the GARFIELD-AF Investigators. **Changes in anticoagulant prescription in Dutch patients with recent-onset atrial fibrillation: observations from the GARFIELD-AF registry.** *Thrombosis Journal*. 2020; 18:5. <https://thrombosisjournal.biomedcentral.com/articles/10.1186/s12959-020-00218-x>.
23. Dalgaard F, Pieper K, Verheugt FWA, Camm AJ, Fox KAA, Kakkar AK, Pallisgaard JL, Rasmussen PV, van Weert H, Lindhardt TB, Torp-Pedersen C, Gislason GH, Ruwald MH, Harskamp RE. **GARFIELD-AF model for prediction of stroke and major bleeding in atrial fibrillation: a Danish nationwide validation study.** *BMJ Open* 2019;9:e033283. <https://bmjopen.bmj.com/content/9/11/e033283>.
24. Fox KAA, Velentgas P, Camm AJ, Bassand J-P, Fitzmaurice DA, Gersh BJ, Goldhaber SZ, Goto S, Haas S, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Dabrowski E, Luo K, Gibbs L, Kakkar AK, for the GARFIELD-AF Investigators. **Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation.** *JAMA Network Open*. 2020;3(2):e200107.
25. Goto S, Goto S, Pieper KS, Bassand J-P, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Haas S, Parkhomenko A, Oto A, Misselwitz F, Turpie AGG, Verheugt FWA, Fox KAA, Gersh BJ, Kakkar AK for the GARFIELD-AF Investigators. **New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF.** *European Heart Journal - Cardiovascular Pharmacotherapy* 2020;6(5):301-9. <https://doi.org/10.1093/ehjcvp/pvz076>.
26. Verbrugge FH, Martin A-C, Siegal D, Fiarresga A, Pieper KS, Illingworth L, Camm AJ, Fox KAA, Bassand J-P, Haas S, Goldhaber SZ, Kakkar AK, **Impact of Oral Anticoagulation in Atrial Fibrillation Patients at Very Low Thromboembolic Risk,** *Heart*. 2019. <http://dx.doi.org/10.1136/heartjnl-2019-315873>.
27. Hacke W, Bassand J-P, Virdone S, Camm AJ, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S, Haas S, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK, for the GARFIELD-AF Investigators. **Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry.** *International Journal of Stroke* 2020;15(3):308-317. 10.1177/1747493019891516.
28. Verheugt FWA, Ambrosio G, Atar D, Bassand J-P, Camm AJ, Costabel JP, Fitzmaurice DA, Illingworth L, Goldhaber SZ, Goto S, Haas S, Jansky P, Kayani G, Stepinska J, Turpie AGG, van Eickels M, Kakkar AK, for the GARFIELD-AF Investigators. **Outcomes in newly diagnosed atrial fibrillation and history of acute coronary syndromes: insights from GARFIELD-AF.** [https://www.amjmed.com/article/S0002-9343\(19\)30543-1/fulltext](https://www.amjmed.com/article/S0002-9343(19)30543-1/fulltext).
29. Atar D, Berge E, Le Heuzey, Virdone S, Camm AJ, Steffel J, Gibbs H, Goldhaber SZ, Goto S, Kayani G, Misselwitz F, Stepinska J, Turpie AGG, Bassand J-P, Kakkar AK, for the GARFIELD-AF investigators. **The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events.** *Europace*. 2019; 0: 1–10. <http://openaccess.sgul.ac.uk/111442/1/euz292.pdf>.
30. Haas S, Camm AJ, Bassand J-P, Angchaisuksiri P, Cools F, Corbalan R, Gibbs H, Jacobson B, Koretsune Y, Mantovani LG, Misselwitz F, Panchenko E, Ragy HI, Stepinska J, Turpie AGG, Sawhney JPS, Steffel J, Lim TW, Pieper KS, Virdone S, Verheugt FWA, Kakkar AK, for the GARFIELD-AF Investigators. **Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF.** *AHJ*. 2019; 213; 35-46. <https://www.sciencedirect.com/science/article/pii/S0002870319300791?via%3Dihub>.

31. Corbalan R, Bassand J-P, Illingworth L, Ambrosio G, Camm AJ, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S, Haas S, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Kakkar AK, for the GARFIELD-AF Investigators. **Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients with Atrial Fibrillation a Report from the GARFIELD-AF Registry.** JAMA Cardiol. 2019; 4(6):526-548. doi: <https://doi.org/10.1001/jamacardio.2018.4729>.
32. Jerjes-Sanchez C, Corbalan R, Barretto ACP, Luciardi HL, Jagan A, Illingworth L, Pieper KS, Kayani G, for the GARFIELD-AF Investigators. **Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: Insights from the GARFIELD-AF registry.** Clinical Cardiology. 2019; 42:553–560. <https://onlinelibrary.wiley.com/doi/full/10.1002/clc.23176>.
33. Goto S, Angchaisuksiri P, Bassand J-P, Camm AJ, Dominguez H, Illingworth L, Gibbs H, Goldhaber SZ, Goto S, Jing J-Z, Haas S, Kayani G, Koretsune Y, Lim T.W, Oh S, Sawhney JPS, Turpie AGG, van Eickels M, Verheugt F.W.A, Kakkar AK, for the GARFIELD-F Investigators. **Management and 1-Year outcomes of patients with newly diagnosed atrial fibrillation and chronic kidney disease: results from the prospective GARFIELD-AF registry.** J AM Heart Assoc. 2019; 8:e105 10. <https://www.ahajournals.org/doi/10.1161/JAHA.118.010510>.
34. Bassand J-P, Virdone S, Goldhaber SZ, Camm AJ, Fitzmaurice D.A, Fox KAA, Goto S, Haas S, Hacke W, Kayani G, Mantovani L.G, Misselwitz F, Pieper KS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK, for the GARFIELD-AF investigators. **Early risks of death, stroke/systemic embolism and major bleeding in patients with newly diagnosed atrial fibrillation: Results from the GARFIELD-AF registry.** Circulation. 2019; 139:787–98. <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.035012>.
35. Koretsune Y, Etoh T, Katsuda Y, Suetsugu T, Kumeda K, Sakuma I, Eshima K, Shibuya M, Ando S, Yokota N, Goto S, Piper KS, Jagan A, Kakkar AK, for the GARFIELD-AF investigators. **Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in Japan: Insights from the GARFIELD-AF Registry.** Circulation Journal 2019; 83(1);67-74. [10.1253/circj.CJ-18-0655](https://doi.org/10.1253/circj.CJ-18-0655).
36. Sawhney JPS, Kothiwale V.A, Bisne V, Durgaprasad R, Jadhav P, Chopda M, Vanajakshamma V, Meena R, Vijayaraghavan G, Chawala K, Jagan A, Pieper KS, Camm AJ, Kakkar AK, for the GARFIELD-AF investigators. **Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights into the GARFIELD-AF Registry.** Indian Heart Journal 2018;70(6):828-35.<https://doi.org/10.1016/j.ihj.2018.09.001>.
37. Cools F, Wollaert B, Vervoort G, Verstraete S, Voet J, Hermans J, Heyse A, De Wolf A, Hollanders G, Boussy T, Anné W, Vercammen J, Faes D, Beutels M, Mairesse G, Purnode P, Blankoff I, Vandergoten P, Capiou L, Allu J, Bassand J-P, Kayani G, for the GARFIELD-AF Investigators. **Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry.** Acta Cardiol. 2018 Oct 27:1-10. <https://www.ncbi.nlm.nih.gov/pubmed/30369290>.
38. Le Heuzeya J-Y, Bassand J-P, Berneau J-P, Cozzolino P, D'Angiolella L, Doucet B, Mantovani LG, Martelet M, Mouallem J, Muller JJ, Pieper KS, for the GARFIELD-AF Investigators. **Stroke prevention, 1-year clinical outcomes, and healthcare resource utilisation in patients with atrial fibrillation in France: data from the GARFIELD-AF registry.** Arch Cardiovasc Dis (2018). <https://doi.org/10.1016/j.acvd.2018.03.012>.
39. Apenteng PN, Gao H, Hobbs FDR, Fitzmaurice DA, on behalf of UK GARFIELD-AF Investigators and GARFIELD-AF Steering Committee. **Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry.** BMJ Open 2018; 8:e018905.
40. Bassand JP, Accetta G, Al Mahmeed W, Corbalan R, Eikelboom J, Fitzmaurice DA, Fox KAA, Gao H, Goldhaber SZ, Goto S, Haas S, Kayani G, Pieper K, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK, GARFIELD-AF Investigators. **Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation.** PLoS One 2018; 25:13(1):e0191592. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784935/pdf/pone.0191592.pdf>.
41. Verheugt F.W.A, Gao H, Mahmeed W.A, Ambrosio G, Angchaisuksiri P, Atar D, Bassand J.P, Camm AJ, Cools F, Eikelboom J, Kayani G, Lim TW, Misselwitz F, Pieper KS, Eickels MV, Kakkar AK, for the GARFIELD-AF

- Investigators. **Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: Insights from the GARFIELD-AF registry.** *E Heart Journal* 2018; 39(6): 464–473. <https://doi.org/10.1093/eurheartj/ehx730>.
42. Panchenko EP, Accetta G, Libis PA, Miller OH, Novikova TN, Nagibovich OA, on behalf of the Russian participants in the register GARFIELD-AF. **Risk Factors and Prescribed Antithrombotic Therapy in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation in Russian Population: Data From the GARFIELD-AF Registry.** *Kardiologija* 2017; 4: 38-44 DOI: <https://doi.org/10.18565/cardio.2017.4.38-44>.
43. Steinberg BA, Gao H, Shrader P, Pieper K, Thomas L, Camm AJ, Ezekowitz MD, Fonarow GC, Bernard J, Gersh B.J, Goldhaber S, Haas S, Hacke W, Peter R, Kowey PR, Ansell J, Kenneth W, Mahaffey KW, Naccarelli G, Reiffel J.A, Turpie AGG, FreekVerheugt FWA, Piccini JP, Kakkar AK, Peterson ED, Fox KAA, For the GARFIELD-AF ORBIT-AF Investigators. **International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries.** *Am Heart J* 2017;194:132-40 [http://www.ahjonline.com/article/S0002-8703\(17\)30241-7/pdf](http://www.ahjonline.com/article/S0002-8703(17)30241-7/pdf).
44. Fox KAA, Lucas JE, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Oto A, Mantovani LG, Misselwitz F, Piccini JP, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators. **Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.** *BMJ Open*. 2017 Dec 21;7(12):e017157. doi: [10.1136/bmjopen-2017-017157](https://doi.org/10.1136/bmjopen-2017-017157).
45. Corbalán R, Conejeros C, Rey C, Stockins B, Eggers G, Astudillo C, Lanas F, Potthoff S, Houzvic C, Montecinos H, Charme G, Bugeño C, Aguilar J, Arriagada G, Marín P, Larico M, en representación del Grupo GARFIELD AF. **Características basales, manejo de terapias antitrombóticas y pronóstico de pacientes chilenos con FA no valvular. Lecciones del Registro GARFIELD AF en Chile.** *Rev Med Chil* 2017; 145: 963-71 [Article in Spanish]. <http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/5977/3293>.
46. Fox KAA, Accetta G, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Kayani G, Kakkar AK; GARFIELD-AF Investigators. **Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).** *Eur Heart J Qual Care Clin Outcomes* 2017 Aug 16. doi: [10.1093/ehjqcco/qcx030](https://doi.org/10.1093/ehjqcco/qcx030). <https://academic.oup.com/ehjqcco/article-lookup/doi/10.1093/ehjqcco/qcx030>.
47. Fox KAA, Gersh BJ, Traore S, Camm AJ, Kayani G, Krogh A, Shweta S, Kakkar AK, for the GARFIELD-AF Investigators. **Evolving quality standards for large-scale registries: the GARFIELD-AF experience.** *Eur Heart J Qual Care Clin Outcomes* 2017; 3: 114-22. <https://academic.oup.com/ehjqcco/article-abstract/3/2/114/2687709>.
48. Camm AJ, Accetta G, Al Mahmeed W, Ambrosio G, Goldhaber SZ, Haas S, Jansky P, Kayani G, Misselwitz F, Oh S, Oto A, Raatikainen P, Steffel J, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. **Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry.** *BMJ Open* 2017; 7: e014579. <http://bmjopen.bmj.com/content/7/3/e014579>.
49. Camm AJ, Accetta G, Ambrosio G, Atar D, Bassand J.P, Berge E, Cools F, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Kayani G, Koretsune Y, Mantovani L.G, Misselwitz F, Oh S, Turpie AG, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. **Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.** *Heart* 2017; 103: 307-14. <http://heart.bmj.com/content/early/2016/09/19/heartjnl-2016-309832.long>.
50. Oh S, Goto S, Accetta G, Angchaisuksiri P, Camm AJ, Cools F, Haas S, Kayani G, Koretsune Y, Lim TW, Misselwitz F, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. **Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: real-world data from the GARFIELD-AF**

registry. Int J Cardiol 2016; 223: 543-7. [http://www.internationaljournalofcardiology.com/article/S0167-5273\(16\)31942-8/abstract](http://www.internationaljournalofcardiology.com/article/S0167-5273(16)31942-8/abstract)

51. Haas S, Ten Cate H, Accetta G, Angchaisuksiri P, Bassand J.P, Camm AJ, Corbalan R, Darius H, Fitzmaurice DA, Goldhaber SZ, Goto S, Jacobson B, Kayani G, Mantovani L.G, Misselwitz F, Pieper K, Schellong SM, Stepinska J, Turpie AG, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. **Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry.** PLoS One 2016; 11: e0164076. <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0164076>.
52. Bassand J.P, Accetta G, Camm AJ, Cools F, Fitzmaurice D.A, Fox K,A, Goldhaber SZ, Goto S, Haas S, Hacke W, Kayani G, Mantovani LG, Misselwitz F, Ten Cate H, Turpie AG, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. **Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.** Eur Heart J 2016; 37: 2882-9. <http://eurheartj.oxfordjournals.org/content/early/2016/06/28/eurheartj.ehw233>.
53. Ten Cate V, Ten Cate H, Verheugt F.W. **The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF): exploring the changes in anticoagulant practice in patients with non-valvular atrial fibrillation in the Netherlands.** Neth Heart J 2016; 24: 574-80. Doi: 10.1007/s12471-016-0874-y.
54. Fitzmaurice DA, Accetta G, Haas S, Kayani G, Lucas Luciard H, Misselwitz F, Pieper K, Ten Cate H, Turpie AG, Kakkar AK; GARFIELD-AF Investigators. **Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists.** Br J Haematol 2016; 174: 610-23. <http://onlinelibrary.wiley.com/doi/10.1111/bjh.14084/abstract>.
55. Stępińska J, Kremis E, Konopka A, Woźakowska-Kapłon B, Ruszkowski P, Kukla P, Kayani G. **Stroke prevention in AF patients in Poland and other European countries: insights from the GARFIELD-AF registry.** Kardiol Pol 2016; 74: 362-71. <https://ojs.kardiologiapolska.pl/kp/article/view/9383>.
56. Haas S; im Namen des GARFIELD-AF Steering Committee. **[GARFIELD-AF - First data on healthcare of patients with atrial fibrillation in Germany].** Dtsch Med Wochenschr 2015; 140: S13-4 [Article in German]. <https://www.thieme-connect.com/DOI/DOI?10.1055/s-0041-101750>.
57. Lip GY, Rushton-Smith SK, Goldhaber SZ, Fitzmaurice DA, Mantovani LG, Goto S, Haas S, Bassand JP, Camm AJ, Ambrosio G, Janský P, Mahmeed WA, Oh S, van Eickels M, Raatikainen P, Steffel J, Oto A, Kayani G, Accetta G, Kakkar AK; for the GARFIELD-AF Investigators. **Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation.** Circ Cardiovasc Qual Outcomes 2015; 8: S12-20. http://circoutcomes.ahajournals.org/content/8/2_suppl_1/S12.long.
58. Sun Y, Hu D; Chinese Investigators of GARFIELD. **[Chinese subgroup analysis of the global anticoagulant registry in the FIELD (GARFIELD) registry in the patients with non-valvular atrial fibrillation].** Zhonghua Xin Xue Guan Bing Za Zhi 2014; 42: 846-50 [Article in Chinese]. http://www.cjcv.org.cn/xinxueguan20144210/33942.htm?locale=zh_CN.
59. Kakkar AK, Mueller I, Bassand J-P, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GYH, Mantovani LG, Turpie AGG, van Eickels M, Misselwitz F, Rushton-Smith S, Kayani G, Wilkinson P, Verheugt FWA, for the GARFIELD Registry Investigators. **Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD Registry.** PLOS ONE 2013; 8: e63479. <http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0063479>.
60. Apenteng PN, Murray ET, Holder R, Hobbs FDR, Fitzmaurice DA; UK GARFIELD Investigators and GARFIELD Steering Committee. **An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol.** BMC Cardiovascular Disorders 2013; 13: 31. UK protocol paper <http://www.biomedcentral.com/1471-2261/13/31>.

61. Kakkar AK, Mueller I, Bassand J-P, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GYH, Mantovani LG, Verheugt FWA, Jamal W, Misselwitz F, Rushton-Smith S, Turpie AGG, for the GARFIELD Registry Investigators. **International longitudinal registry of patients with atrial fibrillation at risk of stroke: GARFIELD (Global Anticoagulant Registry in the FIELD)**. Am Heart J 2012; 163: 13-9.e1. Methods paper
<http://www.ahjonline.com/article/S0002-8703%2811%2900696-X/fulltext>.

1.

1. Alexander GG Turpie, Alfredo E. Farjat, Sylvia Haas, Walter Ageno, Jeffrey I Weitz, Samuel Z Goldhaber, Shinya Goto, Pantep Angchaisuksiri, Gloria Kayani, Renato D Lopes, Chern-En Chiang, Harry Gibbs, Eric Tse, Peter Verhamme, Hugo ten Cate, Juan Muntaner, Sebastian Schellong, Henri Bounameaux, Paolo Prandoni, Ajay K Kakkar. **36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE.** Thrombosis Research, 2022. <https://doi.org/10.1016/j.thromres.2022.11.016>.
2. Haas S, Farjat AE, Pieper K, Ageno W, Angchaisuksiri P, Bounameaux H, Goldhaber SZ, Goto S, Mantovani L, Prandoni P, Schellong S, Turpie AGG, Weitz JI, MacCallum P, Cate HT, Panchenko E, Carrier M, Jerjes-Sanchez C, Gibbs H, Jansky P, Kayani G, Kakkar AK; GARFIELD-VTE investigators. **On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease.** TH Open. 2022 Nov 3;6(4):e354-e364. doi: 10.1055/s-0042-1757744.
3. Cohen O, Ageno W, Farjat AE, Turpie AGG, Weitz JI, Haas S, Goto S, Goldhaber SZ, Angchaisuksiri P, Gibbs H, MacCallum P, Kayani G, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK; GARFIELD-VTE investigators. **Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD-VTE.** J Thromb Haemost. 2022 Feb;20(2):366-374. <https://doi.org/10.1111/jth.15574>.
4. Weitz JI, Farjat AE, Ageno W, Turpie AGG, Haas S, Goto S, Goldhaber SZ, Angchaisuksiri P, Gibbs H, MacCallum P, Carrier M, Kayani G, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK; GARFIELD-VTE Investigators. **Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE.** J Thromb Haemost. 2021 Dec;19(12):3031-3043. <https://doi.org/10.1111/jth.15520>.
5. Goto S, Turpie AGG, Farjat AE, Weitz JI, Haas S, Ageno W, Goldhaber SZ, Angchaisuksiri P, Kayani G, MacCallum P, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK; GARFIELD-VTE investigators. **The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE** <https://doi.org/10.1016/j.thromres.2021.05.007>.
6. Angchaisuksiri P, Goto S, Farjat AE, Fryk H, Bang SM, Chiang CE, Jing ZC, Kondo K, Sathar J, Tse E, Phusanti S, Kayani G, Weitz JI, Ageno W, Goldhaber SZ, Kakkar AK. **Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE.** Thromb Res. 2021 May;201:63-72. <https://doi.org/10.1016/j.thromres.2021.02.024>.
7. Ageno W, Farjat A, Haas S, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Dalsgaard Nielsen J, Kayani G, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK. **Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD-VTE.** Res Pract Thromb Haemost. 2021 Feb 20;5(2):326-341. <https://doi.org/10.1002/rth2.12482>.
8. Jerjes-Sánchez C, Rodriguez D, Farjat AE, Kayani G, MacCallum P, Lopes RD, Turpie AGG, Weitz JI, Haas S, Ageno W, Goto S, Goldhaber SZ, Angchaisuksiri P, Nielsen JD, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK; GARFIELD-VTE investigators. **Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE.** TH Open. 2021 Jan 27;5(1):e24-e34. <https://doi.org/10.1055/s-0040-1722611>.
9. Goto S, Haas S, Ageno W, Goldhaber SZ, Turpie AGG, Weitz JI, Angchaisuksiri P, Nielsen JD, Kayani G, Farjat A, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK; GARFIELD-VTE Investigators. **Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease.** JAMA Netw Open. 2020 Oct 1;3(10):e2022886. <https://doi.org/10.1001/jamanetworkopen.2020.22886>.
10. Weitz JI, Haas S, Ageno W, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Nielsen JD, Kayani G, Farjat AE, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK. **Cancer Associated Thrombosis in Everyday Practice: Perspectives from GARFIELD-VTE.** TH Open. 2021 Jan 27;5(1):e24-e34. <https://doi.org/10.1055/s-0040-1722611>.

11. Bounameaux H, Haas S, Farjat AE, Ageno W, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Nielsen JD, Kayani G, Schellong S, Mantovani LG, Prandoni P, Kakkar AK. **Comparative Effectiveness of Oral Anticoagulants in Venous Thromboembolism: GARFIELD-VTE.** *Thromb Res.* 2020 Jul;191:103-112. Epub 2020 Apr. <https://doi.org/10.1016/j.thromres.2020.04.036>.
12. Schellong S, Goldhaber SZ, Weitz JI, Ageno W, Bounameaux H, Turpie AGG, Angchaisuksiri P, Haas S, Goto S, Zaghdoun A, Farjat A, Nielsen JD, Kayani G, Mantovani LG, Prandoni P, Kakkar AK. **Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry.** *Thromb Haemost.* 2019 Oct;19(10):1675-1685. <https://doi.org/10.1055/s-0039-1693461>. (Cited by 6)
13. Ageno W, Haas S, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Nielsen JD, Kayani G, Pieper KS, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK. **Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry.** *Thromb Haemost.* 2019 Aug;119(8):1365-1372. <https://doi.org/10.1055/s-0039-1688828>. (Cited by 6)
14. Haas S, Ageno W, Weitz JI, Turpie AGG, Goto S, Angchaisuksiri P, Dalsgaard Nielsen J, Kayani G, Zaghdoun A, Farjat AE, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK. **Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients.** *J Thromb Haemost.* 2019 Oct;17(10):1694-1706. <https://doi.org/10.1111/jth.14548>. (Cited by 5)
15. Ageno W, Haas S, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Nielsen JD, Kayani G, Pieper KS, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK. **Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry.** *Thromb Haemost.* 2019 Feb;119(2):319-327. <https://doi.org/10.1055/s-0038-1676611>. (Cited by 23)
16. Weitz JI, Haas S, Ageno W, Angchaisuksiri P, Bounameaux H, Dalsgaard Nielsen J, Goldhaber SZ, Goto S, Kayani G, Mantovani L, Prandoni P, Schellong S, Turpie AGG, Kakkar AK. **Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design.** *Thromb Haemost.* Nov 30 2016;116(6):1172-1179. 10.1160/TH16-04-0335. (Cited by 31)

1. Beyer-Westendorf J, Camm AJ, Fox KAA, Le Heuzey J-Y, Haas S, Turpie AGG, Virdone S, Kakkar AK, for the RIVER Registry Investigators. **International Longitudinal Registry of Patients with Atrial Fibrillation and Treated with Rivaroxaban: RIVaroxaban Evaluation in Real Life setting (RIVER)**. *Thromb J*. 2019 Apr 25;17:7. <https://doi.org/10.1186/s12959-019-0195-7>.

1. Kakkar AK, Bauersachs R, Falanga A, Wong J, Kayani G, Kahnney A, Hughes R, Levine M. **Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey. The Oncologist. 2020; 25:1-7.**
<https://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2019-0676>.

1. Frank Cools, Saverio Virdone, Jitendra Sawhney, Renato D Lopes, Barry Jacobson, Juan I Arcelus, F D Richard Hobbs, Harry Gibbs, Jelle C L Himmelreich, Peter MacCallum, Sebastian Schellong, Sylvia Haas, Alexander G G Turpie, Walter Ageno, Ana Thereza Rocha, Gloria Kayani, Karen Pieper, Ajay K Kakkar, Ajit Avhad, Murillo Antunes, Ana Thereza Rocha, Jesus Gonzales Lama, Atul Abyankar, Adrian Paulo Morales Kormann, Louis Van Zyl, Upendra Kaul, Frances Adams, Ivan Aloysius, Matthew Capehorn, Pradeep Kumar, Rajesh Mahajan. **Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial.** The Lancet Haematology, 2022 (in press): available online 30 June 2022. [https://doi.org/10.1016/S2352-3026\(22\)00173-9](https://doi.org/10.1016/S2352-3026(22)00173-9).

Other publications

1. Kakkar A, en representación del Comité Directivo y de Publicaciones del Registro GARFIELD/on behalf of the Global GARFIELD Steering Committee and Publication Committee. **Pacientes con fibrilación auricular en riesgo de accidente cerebrovascular. GARFIELD (Global Anticoagulant Registry in the FIELD). Patients with atrial fibrillation at risk of stroke.** Rev Fed Arg Cardiol 2012;41:5-7. (Editorial)
<http://www.fac.org.ar/1/revista/12v41n1/perspectiva/perspec01/kakkar.pdf>
http://www.fac.org.ar/1/revista/12v41n1/perspectiva/perspec01/kakkar_ingles.php
2. Torres PI, Townsend SN, Jerjes-Sanchez Diaz C. **Registro internacional longitudinal de pacientes con fibrilación auricular en riesgo de accidente cerebro vascular: una perspectiva mexicana del registro global de anticoagulación (GARFIELD).** Published October/November 2012. (Book chapter)
3. Aalbers J. **GARFIELD: a window on the real-life treatment of atrial fibrillation - South Africa joins the GARFIELD registry.** Cardiovasc J Afr 2012;23:528. (News update)
http://blues.sabinet.co.za/WebZ/Authorize?sessionid=0:autho=pubmed:password=pubmed2004&/AdvancedQuery?&format=F&next=images/ejour/cardio1/cardio1_v23_n9_a16.pdf

2023

European Society of Cardiology Congress 2023 (Amsterdam, Netherlands, 25–28 August 2023)

1. Camm CJF, Viridone S, Corbalan R, Jerjes Sanchez Diaz C, Oh S, Eikelboom J, Oto A, Fox KAA, Camm AJ, Pieper KS, Goto S, Kakkar AJ. **Relationship between care specialty and atrial fibrillation outcomes in the GARFIELD-AF registry.**

2022

European Society of Cardiology Congress 2022 (Barcelona, Spain, 26–29 August 2022)

1. Freek WA Verheugt, Keith AA Fox, Saverio Viridone, Bernard J Gersh, Sylvia Haas, Karen S Pieper, Gloria Kayani, A John Camm, Alexandr Parkhomenko, Ajay K Kakkar for the GARFIELD-AF investigators. **Differential Efficacy and Safety of Oral Anticoagulation in Atrial Fibrillation Patients with or without Comorbid Vascular Disease: Insights from the GARFIELD-AF registry.**
2. Marita Knudsen Pope, Trygve S Hall, Saverio Viridone, Karen S Pieper, Petr Jansky, Jan Steffel, Dan Atar, A John Camm, Sylvia Haas, Bernard J Gersh, Shinya Goto, Elizaveta Panchenko, Joern Dalsgaard Nielsen, Pantep Angchaisuksiri, Ajay K Kakkar, for the GARFIELD-AF Investigators. **Rhythm versus rate control in patients with newly diagnosed atrial fibrillation: observations from the GARFIELD-registry.**
3. C Escobar Cervantes, AJ Camm, S Viridone, KAA Fox, JP Bassand, K Pieper, G Kayani, AK Kakkar, for the GARFIELD-AF investigators. **Stroke and bleed related deaths in newly diagnosed atrial fibrillation patients: insights from the GARFIELD-AF registry.**

2021

European Society of Cardiology Congress 2021 (Digital, 27–30 August 2021)

1. Saverio Viridone, Jelle Himmelreich, Karen S Pieper, A. John Camm, Jean -Pierre Bassand, Keith AA Fox, David A Fitzmaurice, Samuel Z. Goldhaber, Shinya Goto, Sylvia Haas, Gloria Kayani, Frank Misselwitz, Alexander GG Turpie, Freek W.A. Verheugt, Ajay K Kakkar, for the GARFIELD-AF Investigators. **Comparative Effectiveness of NOAC vs VKA in Patients Representing Common Clinical Challenges: Results from the GARFIELD-AF Registry.**
2. Jean-Pierre Bassand, Saverio Viridone, Freek WA Verheugt, A John Camm, Frank Cools, Keith AA Fox, Samuel Z. Goldhaber, Shinya Goto, Sylvia Haas, Werner Hacke, Gloria Kayani, Frank Misselwitz, Karen S Pieper, Alexander GG Turpie, Ajay K Kakkar, for the GARFIELD-AF Investigators. **Impact of NOAC and VKA on outcome of patients with newly diagnosed atrial fibrillation and diabetes – A report from the GARFIELD-AF registry.**
3. Jelle CL Himmelreich, Saverio Viridone, A John Camm, Ralf E Harskamp, Karen S Pieper, Keith AA Fox, Jean-Pierre Bassand, David A Fitzmaurice, Samuel Z Goldhaber, Shinya Goto, Sylvia Haas, Frank Misselwitz, Alexander GG Turpie, Freek WA Verheugt, Ajay K Kakkar for the GARFIELD-AF Investigators. **Safety and efficacy of apixaban and rivaroxaban versus warfarin in real-world atrial fibrillation patients are similar to their randomized trials: insights from the GARFIELD-AF registry.**

4. Jelle CL Himmelreich, Saverio Virdone, A John Camm, Ralf E Harskamp, Karen S Pieper, Keith AA Fox, Jean-Pierre Bassand, David A Fitzmaurice, Samuel Z Goldhaber, Shinya Goto, Sylvia Haas, Frank Misselwitz, Alexander GG Turpie, Freek WA Verheugt, Ajay K Kakkar, for the GARFIELD-AF Investigators. **Comparing Rivaroxaban and Apixaban in GARFIELD-AF according to ROCKET AF and ARISTOTLE trial selection criteria.**

2020

European Society of Cardiology Congress (Amsterdam, Netherlands, 31 August–4 September 2020)

1. Camm AJ, Steffel J, Virdone S, Bassand J-P, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S, Haas S, Turpie AGG, Verheugt FWA, Misselwitz F, Kayani G, Pieper KS, Kakkar AK for the GARFIELD-AF Investigators. **Guideline-directed medical therapies for comorbidities among patients with atrial fibrillation: results from GARFIELD-AF.**
2. Camm AF, Camm AJ, Virdone S, Bassand J-P, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S, Haas S, Turpie AGG, Verheugt FWA, Misselwitz F, Kayani G, Pieper KS, Kakkar AK for the GARFIELD-AF Investigators. **The effect of body mass index on clinical outcomes in patients with newly diagnosed atrial fibrillation in the GARFIELD-AF registry.**
3. Cools, F, Johnson D, Pieper KS, Camm AJ, Bassand J-P, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S, Haas S, Turpie AGG, Verheugt FWA, Misselwitz F, Kayani G, Kakkar AK for the GARFIELD-AF Investigators. **Permanent discontinuation of different anticoagulants in patients with atrial fibrillation and the impact on clinical outcome: data from the GARFIELD-AF registry.**
4. Apenteng P, Fitzmaurice DA, Virdone S, Camm AJ, Bassand J-P, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S, Haas S, Turpie AGG, Verheugt FWA, Misselwitz F, Kayani G, Pieper KS, Kakkar AK, for the GARFIELD-AF Investigators. **Clinical outcomes of patients with newly diagnosed atrial fibrillation who refused anticoagulation: findings from the global GARFIELD-AF registry.**

2019

American Heart Association Scientific Sessions (Philadelphia, Pennsylvania, USA, 16–18 November 2019)

1. Pope MK, Atar A, Svilaas A, on behalf of GARFIELD-AF Investigators. **Risk profile, Antithrombotic Treatment and Clinical Outcomes for Nordic Patients with Atrial Fibrillation.**

European Society of Cardiology Congress (Paris, France, 31 August- 4 September 2019)

1. Fox KAA, Virdone S, Pieper K, on behalf of GARFIELD-AF Investigators. **Balancing risk and benefit in patients with atrial fibrillation: the GARFIELD-AF risk score.**
2. Verstraete S, Virdone S, J Bassand J-P, Cools F, Pieper K, Kayani G, Kakkar AK, on behalf the GARFIELD-AF Investigators. **Haematuria is not elevated in AF patients treated with NOACs versus VKAs: GARFIELD-AF study.**

Late Breaking Abstracts

3. Bassand J-P, Illingworth L, Badoz M, Camm AJ, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S, Haas S, Hacke W, Mantovani LG, Pieper K,S, Turpie AGG, Verheugt FWA, Kakkar AK, on behalf of GARFIELD-AF Investigators. **Early**

and late prognostic implications of bleeding in patients with newly diagnosed atrial fibrillation: Real world evidence from the GARFIELD-AF registry.

4. Lim TW, Camm AJ, Virdone S, Singer DE, Bassand J-P, Fonarow GC, Fox KAA, Ezekowitz M, Gersh BJ, Hylek E, Kakkar AK, Mahaffey KW, Pieper KS, Peterson ED, Piccini JP, on behalf of GARFIELD-AF and ORBIT-AF Investigators. **Predictors of intracranial haemorrhage in patients with atrial fibrillation treated with oral anticoagulants: results from the GARFIELD-AF and ORBIT-AF registries.**

2018

European Society of Cardiology Congress (Munich, Germany, 25–29 August 2018)

1. Keith AA Fox, Berchuck S, Camm AJ, Bassand J-P, Fitzmaurice DA, Gersh BJ, Goldhaber SZ, Goto S, Haas S, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Kakkar AK, for the GARFIELD-AF Investigators. **Evaluation of the effect of oral anticoagulants on all-cause mortality within 3 months of the diagnosis of atrial fibrillation: Results from the GARFIELD-AF prospective registry.**
2. Cozzolino P, Ambrosio G, Bassand J-P, Ten Cate H, Cools F, Darius H, Fitzmaurice D, Haas J, Le Heuzey J-Y, Agnelli G, Rosenkvist M, Stepinska J, Vinolas X, Mantovani LG, Kakkar AK. **The economic burden attributable to atrial fibrillation in nine European countries: perspectives from the GARFIELD-AF registry.**
3. Camm AJ, Cools F, Virdone S, Bassand J-P, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S, Haas S, Mantovani LG, Pieper K, Turpie AGG, Verheugt FWA, Kakkar AK, for the GARFIELD-AF Investigators. **The effect of non-recommended dosing of non-vitamin K antagonist oral anticoagulants (NOACs) on 1-year mortality in patients with newly diagnosed AF? Results from the GARFIELD-AF registry.**
4. Schirripa V, Radic P, Pieper KS, Illingworth L, Le Heuzey J-Y, Jansky P, Fitzmaurice DA, Connolly S, Cappato R, Camm AJ, Atar D, Kakkar AK. **Role of cardioversion in the management of non-valvular atrial fibrillation: insights from the GARFIELD-AF registry.**
5. Siegal DM, Verbrugge F, Martin A-C, Fiarresga A, Camm AJ, Pieper K, Fox KAA, Bassand J-P, Haas S, Goldhaber SZ, Kakkar AK. **Why do clinicians withhold anticoagulation in patients with atrial fibrillation and CHA2DS2 Vasc score ≥ 2 ?**
6. Verbrugge F, Martin A.C, Siegal D, Fiarresga A, Pieper K, Camm J, Fox KAA, Bassand J-P, Haas S, Goldhaber SZ, Kakkar AK. **Why do clinicians prescribe oral anticoagulation in patients with atrial fibrillation despite a low CHA2DS2-VASc score?**

Late Breaking Abstracts

7. Fox KAA, Velentgas P, Camm AJ, Bassand J-P, Fitzmaurice DA, Gersh BJ, Goldhaber SZ, Goto S, Haas S, Misselwitz F, Pieper K, Turpie AGG, Verheugt FWA, Kakkar AK, for the GARFIELD-AF Investigators. **Adverse one-year outcomes for patients newly treated with oral anticoagulants plus antiplatelet therapy after a diagnosis of atrial fibrillation: Results from the GARFIELD-AF prospective registry.**
8. John Camm AJ, Fox KAA, Virdone S, Bassand J-P, Fitzmaurice DA, Gersh BJ, Goldhaber SZ, Goto S, Haas S, Misselwitz F, Pieper K, Turpie AGF, Verheugt FWA, Kakkar AK, for the GARFIELD-AF Investigators. **Comparative effectiveness of oral anticoagulants in everyday practice: Results from the GARFIELD-AF prospective registry.**

World Stroke Congress (Montreal, Canada, 17–20, October 2018)

1. Hacke W, Bassand J-P, Camm AJ, Fitzmaurice D.A, Goldhaber SZ, Virdone S, Goto S, Haas S, Kayani G, Mantovani L.G, Pieper L.G, Misselwitz F, Van Eickels M, Turpie AGG, Verheugt FWA, Kakkar AK, for the GARFIELD-AF Investigators. **In newly diagnosed atrial fibrillation patients, a history of stroke is a better predictor of events than a history of TIA.**

American Heart Association Scientific Sessions (Chicago, USA, 10–14 November 2018)

1. Cools F, Camm AJ, Bassand J-P, Verheugt F.W.A, Yang S, Tsiatis A, Fitzmaurice D.A, Goldhaber SZ, Goto S, Haas S, Misselwitz F, Turpie AGG, Fox KAA, Kakkar AK, for the GARFIELD-AF Investigators. **The risk of permanent discontinuation of oral anticoagulation in patients with atrial fibrillation: data from the GARFIELD-AF registry**

2017

American College of Cardiology Annual Scientific Session (Washington DC, USA, 17–19 March 2017)

1. Camm AJ, Accetta G, Agnelli G, Bassand J.-P, Goldhaber S, Kayani G, Misselwitz F, Oh S, Raatikainen P, Turpie A, van Eickels M, Kakkar A. **Treatment and outcomes of patients with nonvalvular atrial fibrillation according to guideline-defined anticoagulation thresholds: results from the GARFIELD-AF registry.** JACC 2017;69:364. P1110-098, 17 March 2017. <http://www.sciencedirect.com/science/article/pii/S0735109717337531>.
2. Goldhaber SZ, Camm AJ, Accetta G, Bassand J.-P, Fitzmaurice D, Goto S, Haas S, Hacke W, Kayani G, Misselwitz F, Mantovani L, Turpie A, van Eickels M, Verheugt F, Kakkar A. **Early mortality in patients with new onset atrial fibrillation: results from the GARFIELD-AF registry.** JACC 2017;69:315. P1134M-11, 17 March 2017. <http://www.sciencedirect.com/science/article/pii/S073510971733704X>.
3. Verheugt FWAA, Al Mahmeed W, Ambrosio G, Angchaisuksiri P, Atar D, Bassand J-P, Camm AJ, Cools F, Eikelboom JW, Gao H, Kayani G, Lim TW, Misselwitz F, van Eickels M, Kakkar A. **The prescribing of antiplatelet therapy only in patients with nonvalvular atrial fibrillation: results from the GARFIELD-AF registry.** JACC 2017;69:326. P1223M-05, 18 March 2017. <http://www.sciencedirect.com/science/article/pii/S0735109717337154>.

European Heart Rhythm Association EUROPACE-CARDIOSTIM (Vienna, Austria, 18–21 June 2017)

1. Camm AJ, Haas S, Ambrosio G, Kayani G, Koretsune Y, Le Heuzey J-Y, Misselwitz F, Parkhomenko A, Pieper K, Stępińska J, van Eickels M, Kakkar AK, for the GARFIELD-AF Investigators. **Patterns and predictors of anticoagulant prescribing for stroke prevention in patients with nonvalvular atrial fibrillation: results from the GARFIELD-AF registry.** Europace 2017;19:iii354–5. 1665, 21 June 2017. https://academic.oup.com/europace/article-abstract/19/suppl_3/iii354/3873308.

European Society of Cardiology Congress (Barcelona, Spain, 26–30 August 2017)

1. Atar D, Le Heuzey J-Y, Accetta G, Bassand J-P, Camm AJ, Corbalan R, Gibbs H, Goldhaber SZ, Goto S, Jones P, Kayani G, Misselwitz F, Stepinska J, Turpie AGG, Kakkar AK, on behalf of GARFIELD-AF Investigators. **Differences in two-year outcomes according to type of atrial fibrillation: results from the GARFIELD-AF registry.** Eur Heart J

2016;37:975. P4601, 28 August 2017.

https://academic.oup.com/eurheartj/article/38/suppl_1/ehx504.P4601/4090645.

2. Camm AJ, Bassand J.-P, Kayani G, Gao H, Kakkak AK, on behalf of GARFIELD-AF Investigators. **Which definition of hypertension best defines thromboembolic risk in patients with atrial fibrillation? Data from the GARFIELD-AF registry.** Eur Heart J 2016;37:774. P3609, 28 August 2017.
https://academic.oup.com/eurheartj/article/38/suppl_1/ehx504.P3609/4090111
3. Corbalan R, Bassand J.-P, Al Mahmeed W, Ambrosio G, Gao H, Gibbs H, Goldhaber SZ, Jerjes-Sanchez C, Le Heuzey J-Y, Panchenko E, Parkhomenko A, Pereira Barretto AC, Steffel J, Stepinska J, Kakkak AK, on behalf of GARFIELD-AF Investigators. **One-year clinical outcomes and management of patients with ischaemic vs non-ischaemic cardiomyopathy and newly diagnosed atrial fibrillation: results from GARFIELD-AF.** Eur Heart J 2016;37:656. P3237, 28 August 2017.
https://academic.oup.com/eurheartj/article/38/suppl_1/ehx504.P3237/4089745/.
4. Gibbs H, Freedman B, Rosenqvist M, Al Mahmeed W, Ambrosio G, Camm AJ, Connolly SJ, Gao H, Jacobson B, Jerjes-Sanchez C, Kayani G, Oto A, Panchenko E, Ragy H, Kakkak AK, on behalf of GARFIELD-AF Investigators. **Similar clinical outcomes of asymptomatic and symptomatic patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.** Eur Heart J 2016;37:976. P4602, 28 August 2017.
https://academic.oup.com/eurheartj/article/38/suppl_1/ehx504.P4602/4090646/.
5. Goldhaber SZ, Bassand J-P, Accetta G, Camm AJ, Goto S, Kayani G, Misselwitz F, Turpie AGG, Kakkak AK, on behalf of GARFIELD-AF Investigators. **Impact of body mass index in newly diagnosed atrial fibrillation in the GARFIELD-AF registry.** Eur Heart J 2016;37:761. P3569, 28 August 2017.
https://academic.oup.com/eurheartj/article/38/suppl_1/ehx504.P3569/4090072.
6. Mantovani L.G, Cozzolino P, Ambrosio G, Ersanli M, Kayani G, Panchenko E, Raatikainen P, Stepinska J, Kakkak AK, on behalf of GARFIELD-AF Investigators. **Global healthcare resource use in 39,670 patients with AF: perspectives from GARFIELD-AF.** Eur Heart J 2016;37:973. P4594, 28 August 2017.
https://academic.oup.com/eurheartj/article/38/suppl_1/ehx504.P4594/4090638.
7. Mantovani LG, Cozzolino P, D'Angiolella L, Agnelli G, Ambrosio G, Camm AJ, Darius H, Fitzmaurice DA, Fox KAA, Kayani G, Keltai M, Le Heuzey J-Y, Pieper KS, Kakkak AK, on behalf of GARFIELD-AF Investigators. **The burden of atrial fibrillation in the more populated European countries: perspectives from the GARFIELD-AF registry.** Eur Heart J 2016;37:976. P4603, 28 August 2017.
https://academic.oup.com/eurheartj/article/38/suppl_1/ehx504.P4603/4090647.

Asia Pacific Heart Rhythm Society (Yokohama, Japan, 14–17 September 2017)

1. Ayabe K, Goto S, Angchaisuksiri P, Camm AJ, Fitzmaurice D.A, Gao H, Goldhaber SZ, Jing Z-C, Kayani G, Koretsune Y, Lim T.W, Misselwitz F, Oh S, Pieper KS, Sawhney JPS, Kakkak AK, for the GARFIELD-AF Investigators. **Risk factor profile and management of patients with diabetes mellitus and newly diagnosed atrial fibrillation in Asia: results from GARFIELD-AF.** O7-2, 14 September 2017.
2. Jing Z-C, Sawhney JPS, Oh S, Goto S, Angchaisuksiri P, Camm AJ, Fox KAA, Gao H, Gersh BJ, Haas S, Kayani G, Koretsune Y, Lim TW, Mantovani L.G, Kakkak AK, for the GARFIELD-AF Investigators. **Baseline characteristics and treatment patterns in patients with newly diagnosed atrial fibrillation in Asian countries: insights from GARFIELD-AF.** O7-3, 14 September 2017.
3. Goto S, Goto S, Angchaisuksiri P, Bassand J-P, Camm AJ, Gao H, Jing Z-C, Kayani G, Koretsune Y, Lim TW, Oh S, Sawhney JPS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkak AK, for the GARFIELD-AF Investigators. **Risk factor profile and management of patients with chronic kidney disease and newly diagnosed atrial fibrillation in Asia: results from GARFIELD-AF.** O21-4, 15 September 2017.

2016

European Society of Cardiology Congress (Rome, Italy, 27–31 August 2016)

1. Fox KAA, Lucas JE, Pieper KS, Bassand J-P, Camm AJ, Fitzmaurice DA, Hacke W, Kayani G, Oto A, Kakkar AK, on behalf of GARFIELD-AF Investigators. **Identifying patients with atrial fibrillation and “truly low” thromboembolic risk who are poorly characterized by CHA₂DS₂-VASc: superior performance of a novel machine learning tool in GARFIELD-AF.** 7075, 29 August 2016.
2. Fox KAA, Accetta G, Darius H, Goto S, Kayani G, Koretsune Y, Oh S, Parkhomenko A, Sawhney JPS, Stepinska J, Kakkar AK, on behalf of GARFIELD-AF Investigators. **Do baseline characteristics account for geographical variations in event rates in patients with newly diagnosed atrial fibrillation? The GARFIELD-AF registry.** *Eur Heart J* 2016; **37**: 810. P4100, 29 August 2016.
http://eurheartj.oxfordjournals.org/content/ehj/37/suppl_1/599.full.pdf.
3. Goto S, Accetta G, Angchaisuksiri P, Camm AJ, Fitzmaurice D.A, Haas S, Kayani G, Koretsune Y, Lim TW, Oh S, Schellong S.M, ten Cate H, Turpie AGG, Kakkar AK, on behalf of GARFIELD-AF Investigators. **Vitamin K antagonist control for patients with nonvalvular atrial fibrillation in Eastern and Southeastern Asia: an analysis of event rates from GARFIELD-AF.** *Eur Heart J* 2016; **37**: 1007. P4971, 30 August 2016.
http://eurheartj.oxfordjournals.org/content/ehj/37/suppl_1/985.full.pdf.

Belgian Society of Cardiology (Brussels, Belgium, 28–29 January 2016)

1. Cools F, Xhaët O, Striekwold H, De Wolf A, Voet J, Heyse A, Hollanders G, Wollaert B, Vervoort G, Hermans K, Verstraete S, Paparella G, Purnode P, Faes D, Mairesse G, Anné W, Boussy T, Beutels M, Maréchal P, Godart P, Vandergoten P, Vercammen J, Capiiau L, Blankoff I, Balthazar Y, Kakkar AJ. **Evolution over time of antithrombotic therapies in Belgium in patients with newly diagnosed atrial fibrillation: data from the GARFIELD-AF registry.**

German Cardiac Society (Mannheim, Germany, 30 March–2 April 2016)

1. Darius H, Schellong S, Haas S; GARFIELD-DE. **Schlaganfallprävention bei nicht valvulärem VHF im klinischen Alltag in Deutschland – Subanalyse der nationalen Kohorte im GARFIELD-AF Register.** P1817, 2 April 2016.

2015

European Society of Cardiology Congress (London, UK, 29 August–2 September 2015)

1. Oh S, Goto S, Angchaisuksiri P, Camm AJ, Cools F, Haas S, Koretsune Y, Lim TW, Accetta G, Kakkar AK, on behalf of GARFIELD-AF Investigators. **Vitamin K antagonist control in Eastern and Southeastern Asia.** *Eur Heart J* 2015;36:544. 3278, 31 August 2015. http://eurheartj.oxfordjournals.org/content/ehj/36/suppl_1/509.full.pdf.
2. Camm AJ, Ambrosio G, Atar D, Berge E, Cools F, Goldhaber SZ, Kayani G, Koretsune Y, Turpie AGG, Kakkar AK, on behalf of GARFIELD-AF Investigators. **Evolving antithrombotic treatment patterns in patients with newly diagnosed atrial fibrillation in GARFIELD-AF.** *Eur Heart J* 2015;36:745. P4404, 31 August 2015.
http://eurheartj.oxfordjournals.org/content/ehj/36/suppl_1/509.full.pdf.

3. Camm AJ, Ambrosio G, Atar D, Bassand J-P, Cools F, Fox KAA, Jansky P, Keltai M, Le Heuzey J-Y, Kakkar AK, on behalf of GARFIELD-AF Investigators. **Patterns of uptake of non-vitamin K antagonist oral anticoagulants in Europe: an analysis from the GARFIELD-AF registry.** *Eur Heart J* 2015;36:242. P1513, 30 August 2015. http://eurheartj.oxfordjournals.org/content/ehj/36/suppl_1/163.full.pdf.
4. Goto S, Atar D, Bassand J-P, Fox KAA, Goldhaber SZ, Misselwitz F, Oh S, Turpie AGG, Verheugt F, Kakkar AK, on behalf of GARFIELD-AF Investigators. **Stroke, major bleeding and mortality in newly diagnosed atrial fibrillation with moderate-to-severe chronic kidney disease: results from GARFIELD-AF.** *Eur Heart J* 2015;36:987. P5598, 1 September 2015. http://eurheartj.oxfordjournals.org/content/ehj/36/suppl_1/849.full.pdf.

International Society on Thrombosis and Haemostasis Congress (Toronto, Canada, 20–25 June 2015)

1. Kakkar AK, Accetta G, Agnelli G, Angchaisuksiri P, Bassand J-P, Chiswell K, Cools F, Fitzmaurice D.A, Gibbs H, Goldhaber SZ, Goto S, Haas S, Jacobson B, Jerjes-Sanchez C, Kayani G, Mantovani LG, Misselwitz F, ten Cate H, Turpie A.G, van Eickels M, Verheugt FW, Camm J, and on behalf of GARFIELD-AF Investigators. **Risk profiles and 1-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.** *J Thromb Haemost* 2015;13:139. OR119, 22 June 2015. <http://onlinelibrary.wiley.com/doi/10.1111/jth.12993/epdf>.
2. Cate Ht, Haas S, Accetta G, Angchaisuksiri P, Camm J, Corbalan R, Eikelboom J, Fitzmaurice D.A, Goldhaber SZ, Goto S, Jacobson B, Kayani G, Turpie AG, Kakkar AK, and on behalf of GARFIELD-AF Investigators. **Quality of vitamin k antagonist control and 1-year outcomes: a global perspective from the garfield-af registry.** *J Thromb Haemost* 2015;13:130. OR096, 22 June 2015. <http://onlinelibrary.wiley.com/doi/10.1111/jth.12993/epdf>.

2014

European Society of Cardiology Congress (Barcelona, Spain, 30 August–3 September 2014)

1. Bassand J-P, Goldhaber SZ, Camm J, Turpie AGG, Misselwitz F, Oh S, van Eickels M, Agnelli G, Raatikainen P, Kakkar AK, for the GARFIELD Investigators. **Truly low-risk patients with newly diagnosed non-valvular atrial fibrillation at risk of stroke: 1-year outcomes from the GARFIELD Registry.** *Eur Heart J* 2014;35:1108. P6246, 2 September 2014. http://eurheartj.oxfordjournals.org/content/ehj/35/suppl_1/851.full.pdf
2. Haas S, Goto S, Fitzmaurice D, Eikelboom J, ten Cate H, Koretsune Y, Parkhomenko A, Angchaisuksiri P, Corbalan R, Jacobson B, for the GARFIELD Investigators. **International normalized ratio control and 1-year outcomes in patients with newly diagnosed atrial fibrillation: the GARFIELD Registry.** *Eur Heart J* 2014;35:1110. P6256, 2 September 2014. http://eurheartj.oxfordjournals.org/content/ehj/35/suppl_1/851.full.pdf.
3. Bassand J-P, Fitzmaurice D, Camm J, Cools F, Stepinska J, Corbalan R, Kayani G, Panchenko E, Kakkar AK, for the GARFIELD Investigators. **Is cardiovascular death a primary driver of mortality in higher age groups of patients with non-valvular atrial fibrillation? Results from the GARFIELD Registry.** *Eur Heart J* 2014;35:437. P2469, 31 August 2014. http://eurheartj.oxfordjournals.org/content/ehj/35/suppl_1/173.full.pdf.

American Heart Association Scientific Sessions (Chicago, USA, 15–19 November 2014)

1. Camm J, Goldhaber SZ, Ambrosio G, Jansky P, Al Mahmeed W, Oh S, Van Eickels M, Raatikainen P, Steffel J, Chu E, Accetta G, Kayani G, Kakkar AK, for the GARFIELD Investigators. **Impact of gender on clinical outcomes in non-valvular atrial fibrillation: contemporary perspective from the GARFIELD Registry.** *Circulation* 2014;130:A20326. 16 November 2014. http://circ.ahajournals.org/content/130/Suppl_2/A20326.abstract.

- Goto S, Cools F, Verheugt FWA, Lim TW, Turpie AGG, Van Eickels M, Kayani G, Agnelli G, Angchaisuksiri P, Jacobson B, Kakkar AK, for the GARFIELD Investigators. **Event rate in patients with atrial fibrillation who discontinue oral anticoagulant therapy early: results from the GARFIELD Registry.** *Circulation* 2014;130:A19998. 17 November 2014. http://circ.ahajournals.org/content/130/Suppl_2/A19998.abstract.
- Corbalan R, Pereira Barretto AC, Ambrosio G, Al Mahmeed W, Le Heuzey J-Y, Kayani G, Jerjes-Sanchez C, Stepinska J, Parkhomenko A, Steffel J, Panchenko E, Kakkar AK, for the GARFIELD Investigators. **Use of antithrombotic therapies and outcomes in patients with atrial fibrillation and heart failure: insights from the GARFIELD Registry.** *Circulation* 2014;130:A18738. 19 November 2014. http://circ.ahajournals.org/content/130/Suppl_2/A18738.abstract.

2013

Gesellschaft für Thrombose - und Hämostaseforschung (Munich, Germany, 20–23 February 2013)

- Haas S, Darius H, Bassand JP, Fitzmaurice D.A, Goldhaber SZ, Goto S, Hacke W, Lip GYH, Mantovani LG, Verheugt FWA, van Eickels M, Misselwitz F, Rushton-Smith S, Turpie AGG, Kakkar AK, for the GARFIELD Registry Investigators. **Risk profiles and treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: data from the first cohort of the GARFIELD Registry.** P1-16.

American College of Cardiology Annual Scientific Session (San Francisco, CA, USA, 9–11 March 2013)

- Bassand J-P, Rushton-Smith S, Camm AJ, Goldhaber SZ, Goto S, Haas S, Mueller I, Turpie AGG, Kakkar A, for the GARFIELD Investigators. **Atrial fibrillation treatment paradox: characteristics of and first-year events in patients not treated with vitamin K antagonists compared to treated patients. The GARFIELD Registry.** *JACC* 2013;61:E379. P49, 10 March 2013. <http://content.onlinejacc.org/article.aspx?articleid=1664526>.

European Society of Cardiology Congress (Amsterdam, Netherlands, 31 August–4 September 2013)

- Berge E, Atar D, Le Heuzey J-Y, Connolly S, Fitzmaurice DA, Camm AJ, Jansky P, Rushton-Smith SK, Kayani G, Kakkar AK. **Outcomes after rhythm versus rate control in patients with atrial fibrillation: the international prospective GARFIELD Registry.** *Eur Heart J* 2013;34:103. P551, 31 August 2013 http://eurheartj.oxfordjournals.org/content/34/suppl_1/P551.
- Camm AJ, Turpie AGG, Goto S, Stepinska J, Le Heuzey J-Y, Misselwitz F, Corbalan R, Rushton-Smith SK, Kayani G, Kakkar AK. **One-year outcomes in new versus permanent atrial fibrillation: insights from the prospective, international GARFIELD Registry.** *Eur Heart J* 2013;34:954. P5137, 3 September 2013 http://eurheartj.oxfordjournals.org/content/34/suppl_1/P5137.
- Verheugt FWA, Goldhaber SZ, Atar D, Camm AJ, Ambrosio G, Jansky P, Stepinska J, Rushton-Smith SK, Kayani G, Kakkar AK. **Outcomes at 1 year in atrial fibrillation patients with versus without an acute coronary syndrome: insights from the prospective GARFIELD Registry.** *Eur Heart J* 2013;34:669. 3735, 2 September 2013. http://eurheartj.oxfordjournals.org/content/34/suppl_1/3735.
- Goto S, Oh S, Cools F, Koretsune Y, Angchaisuksiri P, Rushton-Smith SK, Kayani G, Wilkinson P, Kakkar AK. **Regional differences in use of antithrombotic therapy for stroke prevention in atrial fibrillation and associated outcomes: European and Asian insights.** *Eur Heart J* 2013;34:790. P4277, 2 September 2013. http://eurheartj.oxfordjournals.org/content/34/suppl_1/P4277.

5. Kakkar AK, Bassand J-P, Goldhaber SZ, Agnelli G, Atar D, Berge E, Cools F, Haas S, Rushton-Smith SK, Hacke W. **One-year outcomes in atrial fibrillation patients with versus without a previous stroke or transient ischaemic attack: findings from the international prospective GARFIELD Registry.** *Eur Heart J* 2013;34:61. P386, 31 August 2013. http://eurheartj.oxfordjournals.org/content/34/suppl_1/P386.
6. Le Heuzey J-Y, Goto S, Verheugt FWA, Cools F, Rushton-Smith SK, Kayani G, Wilkinson P, Kakkar AK. **Direct current conversion and clinical events at 1 year in patients with non-valvular atrial fibrillation. The Global Anticoagulant Registry in the FIELD (GARFIELD).** *Eur Heart J* 2013;34:1045. P5633, 3 September 2013. http://eurheartj.oxfordjournals.org/content/34/suppl_1/P5633.
7. Sanchez Diaz CJ, Goto S, Misselwitz F, Ambrosio G, Rushton-Smith SK, Kayani G, Wilkinson P, Kakkar AK. **One-year outcomes in atrial fibrillation patients with versus without coronary artery disease. The prospective Global Anticoagulant Registry in the FIELD (GARFIELD).** *Eur Heart J* 2013;34:571. P3129, 2 September 2013. http://eurheartj.oxfordjournals.org/content/34/suppl_1/P3129.
8. Turpie AGG, Camm AJ, Goto S, Stepinska J, Le Heuzey J-Y, Misselwitz F, Corbalan R, Rushton-Smith SK, Kayani G, Kakkar AK. **Twelve-month outcomes in paroxysmal versus permanent atrial fibrillation: data from the prospective, international GARFIELD Registry.** *Eur Heart J* 2013;34:738. P4065, 2 September 2013. http://eurheartj.oxfordjournals.org/content/34/suppl_1/P4065.

American Heart Association Scientific Sessions (Dallas, TX, USA, 16–20 November 2013)

1. Goto S, Oh S, Bassand J-P, Gibbs H, Angchaisuksiri P, Rushton-Smith SK, Kayani G, Kakkar AK, Wilkinson P. **Moderate-to-severe chronic kidney disease associated with 1-year all-cause mortality in patients newly diagnosed with non-valvular atrial fibrillation. The prospective international GARFIELD Registry.** *Circulation* 2013;128:A14514. 18 November 2013. http://circ.ahajournals.org/content/128/Suppl_22/A14514.

CARDIAC Society of Australia and New Zealand (CSANZ) Congress (Gold Coast, Australia, 7–11 August 2013)

1. Gibbs H. **One year Australian outcome of cohort 1 of the Global Anticoagulant Registry in the Field (GARFIELD) Study.** CSANZ, 2013. *Heart Lung Circ* 2013;22:S221. A525, 10 August 2013. <http://www.heartlungcirc.org/article/S1443-9506%2813%2900885-8/fulltext>.

2012

American College of Cardiology Annual Scientific Session (Chicago, USA, 24–27 March 2012)

1. Lip G, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Verheugt FWA, Turpie AGG, Mueller I, Rushton-Smith S, Kakkar AK, for the GARFIELD Investigators. **Inappropriate utilization of anticoagulation in patients with atrial fibrillation: the Global Anticoagulant Registry in the FIELD (GARFIELD) Registry.** *J Am Coll Cardiol* 2012;59:E670. P1236-167, 26 March 2012. <http://content.onlinejacc.org/article.aspx?articleid=1204760>.

European Stroke Conference (Lisbon, Portugal, 22–25 May 2012)

1. Hacke W, Bassand JP, Fitzmaurice D.A, Goldhaber SZ, Goto S, Haas S, Lip GYL, Mantovani L, Turpie AGG, Verheugt FWA, Misselwitz F, van Eickels M, Mueller I, Rushton-Smith S, Kakkar AK, for the GARFIELD Investigators. **Gap between evidence-based guidelines and provision of oral anticoagulant therapy among patients newly**

diagnosed with atrial fibrillation: findings from Global Anticoagulant Registry in the FIELD. Cerebrovasc Dis 2012;33:816-17. P820, 24 May 2012.

http://content.karger.com/ProdukteDB/miscArchiv/CED_2012_033_s_2/index.html#/816/.

European Society of Cardiology Congress (Munich, Germany, 25–29 August 2012)

1. Bassand JP, Mueller I, Mantovani LG, Haas S, Goldhaber SZ, Goto S, Lip GYH, Rushton-Smith SK, Kakkar AK, for the GARFIELD Investigators. **Antithrombotic treatment patterns for stroke prevention in relation to age: insights from the Global Anticoagulant Registry in the FIELD (GARFIELD) evaluation.** Eur Heart J 2012;33:52. P557, 26 August 2012. http://eurheartj.oxfordjournals.org/content/ehj/33/suppl_1/19.full.pdf.
2. Verheugt FWA, Bassand JP, Turpie AGG, Fitzmaurice DA, Haas S, Goto S, Lip GYH, Mueller I, Rushton-Smith SK, Kakkar AK, for the GARFIELD Investigators. **Antithrombotic therapy for stroke prevention in patients with newly diagnosed atrial fibrillation and a history of acute coronary syndrome: the Global Anticoagulant Registry in the FIELD (GARFIELD).** Eur Heart J 2012;33:1081. P5748, 29 August 2012. http://eurheartj.oxfordjournals.org/content/ehj/33/suppl_1/941.full.pdf.
3. Lip GYH, Rushton-Smith SK, Goto S, Verheugt FWA, Goldhaber SZ, Haas S, Bassand JP, Mueller I, Kakkar AK, for the GARFIELD Investigators. **Patterns of antithrombotic therapy and type of atrial fibrillation: insights from the Global Anticoagulant Registry in the FIELD (GARFIELD).** Eur Heart J 2012;33:54. P562, 26 August 2012. http://eurheartj.oxfordjournals.org/content/ehj/33/suppl_1/19.full.pdf.
4. Lip GYH, Rushton-Smith SK, Goldhaber SZ, Fitzmaurice DA, Mantovani LG, Goto S, Haas S, Bassand JP, Mueller I, Kakkar AK, for the GARFIELD Investigators. **Gender differences in use of antithrombotic therapy in atrial fibrillation: real-world perspective from the Global Anticoagulant Registry in the FIELD (GARFIELD).** Eur Heart J 2012;33:58. P578, 26 August 2012. http://eurheartj.oxfordjournals.org/content/ehj/33/suppl_1/19.full.pdf.
5. Goto S, Mueller I, Fitzmaurice DA, Haas S, Lip GYH, Turpie AGG, Goldhaber SZ, Rushton-Smith S, Kakkar AK, for the GARFIELD Investigators. **Regional differences in the use of antithrombotic therapy for stroke prevention in atrial fibrillation: European and Asian insights from the Global Anticoagulant Registry in the FIELD (GARFIELD).** Eur Heart J 2012;33:685. P4043, 28 August 2012. http://eurheartj.oxfordjournals.org/content/ehj/33/suppl_1/655.full.pdf.
6. Goto S, Lip GYH, Goldhaber SZ, Verheugt FWA, Bassand JP, Turpie AGG, Mueller I, Rushton-Smith SK, Kakkar AK, for the GARFIELD Investigators. **Impact of renal function on use of antithrombotic therapy in atrial fibrillation: real-world perspective from the global anticoagulant registry in the FIELD.** Eur Heart J 2012;33:967. 5290, 29 August 2012. http://eurheartj.oxfordjournals.org/content/ehj/33/suppl_1/941.full.pdf.

World Stroke Congress (Brasilia, Brazil, 10–13 October 2012)

1. Hacke W, Rushton-Smith S, Mueller I, Kakkar AK, for the GARFIELD Investigators. **Characteristics and treatment of patients newly diagnosed with atrial fibrillation with versus without prior stroke: the global GARFIELD registry.** 12 October 2012.

American Heart Association Scientific Sessions (Los Angeles, USA, 4–6 November 2012)

1. Kakkar AK, **Antithrombotic treatments and associated outcomes in patients with atrial fibrillation: the Global Anticoagulant Registry in the FIELD (GARFIELD).** 7 November 2012. (Clinical Science: Special Reports session)

2. Mantovani L, Mueller I, Bassand J.P, Fitzmaurice D, Goldhaber SZ, Goto S, Haas S, Turpie AGG, Verheugt FWA, Rushton-Smith S, Kakkar AK; for the GARFIELD Investigators. **Outcomes and quality of anticoagulant control in patients newly diagnosed with non-valvular atrial fibrillation: insights from the worldwide GARFIELD Registry.** *Circulation* 2012; 126: A18357. P2171, 6 November 2012
http://circ.ahajournals.org/content/126/Suppl_21/A18357.
3. Gibbs H, Kakkar A. **Atrial fibrillation in Australia – results from the Garfield study.** CSANZ, 2012. *Heart Lung Circ* 2012; 21: S243. A586 <http://www.heartlungcirc.org/article/S1443-9506%2812%2900868-2/fulltext>.
4. Koretsune Y. **Atrial fibrillation and the GARFIELD Registry in Japan.** Japanese Society of Electrocardiology, 2012.
5. Fitzmaurice D, Murray E, Apenteng P, Hobbs R, Kakkar A. **Global Anticoagulant Registry in the Field (Garfield): a snapshot of atrial fibrillation in the UK.** Society for Academic Primary Care, 2012. SP125, 3–4 October 2012.

2011

European Society of Cardiology Congress (Paris, France, 27–31 August 2011)

1. Kakkar AK, on behalf of the Garfield Registry Investigators. **Prospective multicentre international registry of patients newly diagnosed with atrial fibrillation at risk of stroke: the Garfield Registry.** *Eur Heart J* 2011; 32: 566. P3359 (W), 29 August 2011. https://academic.oup.com/eurheartj/article/32/suppl_1/313/471759/Monday-29-August-2011

2022

International Society on Thrombosis and Haemostasis Congress(London, UK, 9–13 July 2022)

1. MacCallum P, Viridone S, Bariana Tahir, Uma Maheshwari Pieper K, Kakkar A. **Predictors of venous thromboembolism in hospitalised COVID-19 patients.**

2021

International Society on Thrombosis and Haemostasis Congress (Philadelphia, USA, 17–21 July 2021)

1. Turpie A, Farjat A, Haas S, Ageno W, Weitz J, Goldhaber S, Goto S, Angchaisuksiri P, Kayani G, Lopes RD, Chiang C, Gibbs H, Tse E, Verhamme P, Cate H, Muntaner J, Schellong S, Bounameaux H, Prandoni P, and Kakkar A, on behalf of the GARFIELD-VTE investigators. **36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE.**
2. Sylvia Haas, Henri Bounameaux, Alfredo E Farjat, Walter Ageno, Jeffrey I Weitz, Samuel Z. Goldhaber, Alexander GG Turpie, Shinya Goto, Pantep Angchaisuksiri, Peter MacCallum, Hugo Ten Cate, Elizaveta Panchenko, Marc Carrier, Carlos Jerjes Sanchez Diaz, Harry Gibbs, Petr Jansky, Gloria Kayani, Sebastian Schellong, Paolo Prandoni, Ajay K Kakkar, on behalf of the GARFIELD-VTE investigators. **Comparative effectiveness of oral anticoagulants in venous thromboembolism: On-treatment analysis in GARFIELD-VTE.**
3. Alfredo E Farjat, Keith AA Fox, Alexander GG Turpie, Samuel Z Goldhaber, Henri Bounameaux, Paolo Prandoni, Jeffrey I Weitz, Gloria Kayani, Pantep Angchaisuksiri, Sylvia Haas, Sebastian Schellong, Walter Ageno, Shinya Goto, Elizaveta Panchenko, Chern-En Chiang, Carlos Jerjes Sanchez Diaz, Juan Muntaner, Peter Verhamme, Eric Tse, and Ajay K Kakkar, on behalf of the GARFIELD-VTE investigators. **Prediction of mortality in recently diagnosed venous thromboembolism patients: The GARFIELD-VTE Mortality Risk Model.**

2020

International Society on Thrombosis and Haemostasis Congress (Milan, Italy, 12–14 July 2022)

1. Shinya Goto, Alexander GG Turpie, Alfredo E. Farjat, Jeffrey I. Weitz, Sylvia Haas, Walter Ageno, Samuel Z. Goldhaber, Pantep Angchaisuksiri, Joern Dalsgaard Nielsen, Gloria Kayani, Peter MacCallum, Sebastian Schellong, Henri Bounameaux, Lorenzo G Mantovani, Paolo Prandoni, Ajay K Kakkar, on behalf of the GARFIELD-VTE investigators. **The Influence of Anemia on Clinical Outcomes in Venous Thromboembolism: Results from GARFIELD-VTE.**
2. Omri Cohen, Walter Ageno, Alfredo E. Farjat, Alexander GG Turpie, Jeffrey I Weitz, Sylvia Haas, Shinya Goto, Samuel Z Goldhaber, Pantep Angchaisuksiri, Harry Gibbs, Peter MacCallum, Joern Dalsgaard Nielsen, Gloria Kayani, Sebastian Schellong, Henri Bounameaux, Lorenzo G Mantovani, Paolo Prandoni, Ajay K Kakkar, on behalf of the GARFIELD-VTE investigators. **Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from the GARFIELD-VTE registry.**
3. Jeffrey I. Weitz, Walter Ageno, Alfredo E. Farjat, Alexander GG Turpie, Sylvia Haas, Shinya Goto, Samuel Z. Goldhaber, Pantep Angchaisuksiri, Harry Gibbs, Peter MacCallum, Marc Carrier, Joern Dalsgaard Nielsen, Gloria Kayani, Sebastian Schellong, Henri Bounameaux, Lorenzo G Mantovani, Paolo Prandoni, Ajay K Kakkar, on behalf

of the GARFIELD-VTE investigators. **Influence of body mass index on outcomes in patients with venous thromboembolism: Insights from GARFIELD-VTE.**

4. Carlos Jerjes-Sánchez, David Rodriguez, Alfredo E. Farjat, Gloria Kayani, Peter MacCallum, Renato D. Lopes, Alexander G. G. Turpie, Jeffrey I. Weitz, Sylvia Haas, Walter Ageno, Shinya Goto, Samuel Z. Goldhaber, Pantep Angchaisuksiri, Joern Dalsgaard Nielsen, Sebastian Schellong, Henri Bounameaux, Lorenzo G Mantovani Paolo Prandoni, Ajay K Kakkar, on behalf of the GARFIELD-VTE investigators. **Pregnancy-associated venous thromboembolism: Insights from GARFIELD-VTE.**

2019

International Society on Thrombosis and Haemostasis Congress (Melbourne, Australia, 6–10 July 2019)

GARFIELD-VTE Symposium

1. Ageno W, Gibbs H, Turpie AGG, Weitz JI, Jacobson B, Kakkar AK, on behalf of the GARFIELD-VTE investigators. **Understanding the Outcomes of Anticoagulation: Insights from the GARFIELD Registries.**
2. Angchaisuksiri P, Bang SM, Fryk H, Chiang CE, Jing ZC, Wang S, Kondo K, Sathar J, Tse E, Goto S, Kakkar AK. **Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE.**
3. Prandoni P, Turpie AGG, Farjat AE, Weitz JI, Haas S, Ageno W, Goldhaber SZ, Goto S, Angchaisuksiri P, Nielsen JD, Kayani G, Schellong S, Bounameaux H, Mantovani LG, Kakkar AK. **Gender-related differences in venous thromboembolism patients: GARFIELD-VTE.**
4. Goto S, Turpie AGG, Zaghdoun A, Weitz JI, Haas S, Ageno W, Goldhaber SZ, Angchaisuksiri P, Nielsen JD, Kayani G, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK. **The influence of renal impairment on clinical outcomes in venous thromboembolism patients enrolled in GARFIELD-VTE.**

63rd Annual Meeting of the Society of Thrombosis and Haemostasis Research (GTH) (Berlin, Germany, 27 February–2 March 2019)

GARFIELD-VTE Symposium

1. Haas S, Ageno W, Darius H, Kayani G, Pieper K, Turpie AGG, Schellong S, Weitz JI, Kakkar AK, on behalf of the GARFIELD-VTE Steering Committee. **Management of venous thromboembolism (VTE) in routine clinical practice - Results from the global GARFIELD-VTE registry.**

2018

10th Congress for the Asian-Pacific Society on Thrombosis and Hemostasis (APSTH) (Sapporo, Japan, 28–30 June 2018)

1. Angchaisuksiri P, MacCallum P, Ageno W, Haas S, Bounameaux H, Goldhaber SZ, Bouliotis G, Kayani G, Dalsgaard Nielsen J, Mantovani LG, Schellong S, Turpie AGG, Prandoni P, Weitz JI, Goto S, Kakkar AJ. **Venous thromboembolism in Asia and worldwide: Emerging insights from the GARFIELD-VTE registry.**

International Society on Thrombosis and Haemostasis Congress (Berlin, Germany, 8–13 July 2017)

1. Ageno W, McCallum P, Haas S, Weitz JI, Angchaisuksiri P, Bounameaux H, Goldhaber SZ, Goto S, Kayani G, Dalsgaard Nielsen J, Mantovani LG, Schellong S, Turpie AGG, Prandoni P, Kakkar AK, on behalf of GARFIELD-VTE investigators. **Clinical characteristics and management of patients with a confirmed diagnosis of venous thromboembolism: the GARFIELD VTE Registry.**
2. Turpie AGG, Haas S, Weitz JI, Ageno W, Angchaisuksiri P, Bounameaux H, Goldhaber SZ, Goto S, Kayani G, Dalsgaard Nielsen J, Schellong S, Mantovani LG, Prandoni P, Kakkar AK, on behalf of GARFIELD-VTE investigators. **6 month outcomes of patients: Results from GARFIELD VTE.**
3. Haas S, Turpie AGG, Weitz JI, Ageno W, Angchaisuksiri P, Bounameaux H, Goldhaber S, Goto S, Kayani G, Dalsgaard Nielsen J, Schellong S, Mantovani LG, Prandoni P, Kakkar AK, on behalf of GARFIELD-VTE investigators. **Anticoagulation treatment patterns of venous thromboembolism in GARFIELD VTE patients.**
4. Weitz JI, Turpie AGG, Haas S, Ageno W, Angchaisuksiri P, Bounameaux H, Goldhaber S, Goto S, Kayani G, Dalsgaard Nielsen, Schellong S, Mantovani LG, Prandoni P, Kakkar AK, on behalf of GARFIELD-VTE investigators. **Clinical characteristics and treatments of patients with cancer associated venous thromboembolism: Results from GARFIELD VTE registry.**



2019

International Society on Thrombosis and Haemostasis Congress (Melbourne, Australia, 6–10 July 2019)

1. Petralia G, Farjat AE, Fryk H, Kakkar AK, on behalf of the PERCEIVE investigators. **Prospective Registry of Cancer and Events Involving Venous Thromboembolism (PERCEIVE): 12 month outcomes.**